Who makes ACH-0145228: Powder-in-capsule?

ACH-0145228: Powder-in-capsule is developed by Alexion Pharmaceuticals, Inc..

What development phase is ACH-0145228: Powder-in-capsule in?

ACH-0145228: Powder-in-capsule is in Phase 1.

Last reviewed 2026-05-15 · How we verify

ACH-0145228: Powder-in-capsule

Alexion Pharmaceuticals, Inc. · Phase 1 active Small molecule

At a glance

Generic name	ACH-0145228: Powder-in-capsule
Also known as	ALXN2050
Sponsor	Alexion Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults (PHASE1)
A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants (PHASE1)
A Study of Multiple Doses of ALXN2050 in Healthy Adults (PHASE1)
A Study of Single-dose ALXN2050 in Healthy Adults (PHASE1)
A Drug Interaction Study of ACH-0145228 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ACH-0145228: Powder-in-capsule CI brief — competitive landscape report
ACH-0145228: Powder-in-capsule updates RSS · CI watch RSS
Alexion Pharmaceuticals, Inc. portfolio CI